Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | PRKCA | P17252 | 4/20 | 0.52 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.52 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.52 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | DGKA | P23743 | 1/20 | 0.49 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3937050 | 0.89 | LMNA (0.70) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL2152312 | 0.84 | LMNA (0.64) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL2152561 | 0.84 | LMNA (0.64) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL2152572 | 0.84 | LMNA (0.64) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL6018541 | 0.84 | LMNA (0.64) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL2152798 | 0.84 | LMNA (0.64) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL18106999 | 0.84 | LMNA (0.64) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL2152823 | 0.84 | LMNA (0.64) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL2152579 | 0.84 | LMNA (0.64) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL218151 | 0.84 | DGKA (0.65) | ALDH1A1LMNATSHRMAPTDGKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3608308-B1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2021-07-21 | — | — | EP | disclosed |
| US-10792361-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2020-10-06 | — | — | US | disclosed |
| EP-3608308-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | Novartis AG (CH) | 2020-02-12 | — | — | EP | disclosed |
| EP-2964608-B1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2019-08-28 | — | — | EP | disclosed |
| US-20180369386-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2018-12-27 | — | — | US | disclosed |
| US-10124065-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2018-11-13 | — | — | US | disclosed |
| US-20160106842-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-04-21 | — | — | US | disclosed |
| US-20160106842-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-04-21 | — | — | US | disclosed |
| US-20160106842-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-04-21 | — | — | US | disclosed |
| EP-2964608-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | Novartis AG (CH) | 2016-01-13 | — | — | EP | disclosed |
| WO-2014136086-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2014-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10124065-B2 | Lipids and lipid compositions for the delivery of active agents | LIPA, LPAR1, LPAR4 | ALDH1A1 2488/4885LMNA 679/4885PRKCA 2977/4885 |
| US-20180369386-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, LPAR1, LPAR4 | ALDH1A1 2488/4885LMNA 679/4885PRKCA 2977/4885 |
| US-20160106842-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, LPAR1, LPAR4 | ALDH1A1 2488/4885LMNA 679/4885PRKCA 2977/4885 |
| US-10792361-B2 | Lipids and lipid compositions for the delivery of active agents | LIPA, LPAR1, LPAR4 | ALDH1A1 2488/4885LMNA 679/4885PRKCA 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.